Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1338042/000119312511084896/d10k.htm
SEC Filings
AEGR Annual Reports
AEGR Quarterly Reports
AEGR Corporate News
Bylaw Change
Change in Assets
Change in Control
Ending Agreement
Event for Officers
Financial Exhibit
Listing Status
New Agreement
Security Holders Change November 2016
Vote of Security Holders November 2016
Earnings Release November 2016
Other Events October 2016
Other Events October 2016
Financial Exhibit
Other Events October 2016
Earnings Release
Financial Exhibit August 2016
Financial Exhibit
Other Events August 2016
Event for Officers
Financial Exhibit
New Agreement
New Costs July 2016
Vote of Security Holders July 2016
Bylaw Change
Change in Assets
Change in Control
Ending Agreement
Event for Officers
Financial Exhibit
Listing Status
New Agreement
Security Holders Change
Change in Assets
Change in Control
Ending Agreement
Event for Officers
Financial Exhibit
Listing Status
New Agreement
Security Holders Change
November 2016
Vote of Security Holders
November 2016
Earnings Release
November 2016
Other Events
October 2016
Other Events
October 2016
Financial Exhibit
Other Events
Other Events
October 2016
Earnings Release
Financial Exhibit
Financial Exhibit
August 2016
Financial Exhibit
Other Events
Other Events
August 2016
Event for Officers
Financial Exhibit
New Agreement
New Costs
Financial Exhibit
New Agreement
New Costs
July 2016
Vote of Security Holders
July 2016
Last10K.com | 10-K Annual Report Thu Mar 31 2011
Exhibit 99.1
FOR IMMEDIATE RELEASE
CONFERENCE CALL DETAILS ON PAGE TWO
AEGERION PHARMACEUTICALS ANNOUNCES
FOURTH-QUARTER AND YEAR-END 2010 FINANCIAL RESULTS
Cambridge, MA, March 2, 2011 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced its financial results and business highlights for the fourth-quarter and year ended December 31, 2010.
Financial Results and Outlook
For the quarter ended December 31, 2010, Aegerion reported a net loss of $12.1 million, or $0.92 per share attributable to common stockholders. For the year ended December 31, 2010, Aegerion reported a net loss of $23.0 million, or $5.07 per share attributable to common stockholders.
Research and development expenses were $4.0 million for the quarter ended December 31, 2010, compared to $2.0 million for the same period in 2009. For the year ended December 31, 2010, research and development expenses were $7.6 million, compared with $7.0 million for the full year 2009. Research and development expenses for both the quarter and the full year were primarily related to the advancement of the Phase III clinical trial for our lead compound, lomitapide.
General and administrative expenses were $2.7 million for the quarter ended December 31, 2010, compared with $0.9 million for the same period in 2009. For the year ended December 31, 2010, general and administrative expenses were $5.9 million, compared with $3.1 million for the full year 2009. This increase was primarily due to increased consulting expenses and outside services relating to late-stage clinical development and public company expenses.
As of December 31, 2010, Aegerion had cash and cash equivalents totaling approximately $44.1 million.
Aegerion expects full-year 2011 cash burn to be between $22.5 and $27.5 million.
This forecast spending level in 2011 anticipates full resourcing to achieve regulatory filing targets in a high quality and timely fashion. Included in this spending level are the one-time pre-clinical and clinical studies necessary to support these filings as well as the near-term pre-commercial resourcing needed to support an optimized launch of lomitapide targeted for 2012.
The following information was filed by Aegerion Pharmaceuticals, Inc. (AEGR) on Wednesday, March 2, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Aegerion Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aegerion Pharmaceuticals, Inc..
Assess how Aegerion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Aegerion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2011 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Material Contracts, Statements, Certifications & more
Aegerion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Exhibit 21.1: Subsidiaries Of Registrant
Exhibit 23.2: Consent Of Ernst &Amp; Young Llp
Exhibit 31.1: Certification Of Chief Executive Officer Of The Company Pursuant To Section 302
Exhibit 31.2: Certification Of President Of The Company Pursuant To Section 302
Exhibit 32.1: Certification Of Ceo Of The Company Pursuant To Section 906
Ticker: AEGR
CIK: 1338042
Form Type: 10-K Annual Report
Accession Number: 0001193125-11-084896
Submitted to the SEC: Thu Mar 31 2011 4:24:00 PM EST
Accepted by the SEC: Thu Mar 31 2011
Period: Friday, December 31, 2010
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/aegr/0001193125-11-084896.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...